Tokai Pharmaceuticals

Parents

Cambridge, Massachusetts
Founded 2008
Has raised $23 million in a Series D3 financing, which included its existing investors Novartis Venture Fund, Apple Tree Partners, and angel investors
Targets prostate cancer cells that become resistant to standard hormone-deprivation therapies
The new money will go toward Tokai’s lone drug in development, galeterone (TOK-001)
Tokai has now raised a total of $57 million since its founding in 2004.
Tokai Snaps Up $23M From Novartis and Apple Tree to Challenge Leaders in Prostate Cancer (2011)
Tokai’s drug hits 3 molecular targets, which gives it a potential advantage over more narrowly targeted drugs marketed by J&J, Takeda Pharmaceuticals and Medivation.